Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 28
- Registration Number
- NCT00313599
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 121
- Registration Number
- NCT00299286
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust, London, United Kingdom
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
- Conditions
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT00272987
- Locations
- 🇧🇪
Novartis Investigative Site, Liege, Belgium
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 242
- Registration Number
- NCT00263588
- Locations
- 🇬🇧
Novartis Investigative Site, Brighton, United Kingdom
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00258050
- Locations
- 🇺🇸
GSK Investigational Site, Chapel Hill, North Carolina, United States
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
- Conditions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00239200
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Gary Schwartz
- Target Recruit Count
- 27
- Registration Number
- NCT00225758
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸North Shore University Hospital, Lake Success, New York, United States
Neoadjuvant GW572016 to Treat Breast Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 49
- Registration Number
- NCT00206427
- Locations
- 🇺🇸
Baylor Breast Center, Houston, Texas, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of New Mexico, Albuquerque, New Mexico, United States
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00158782
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT00148902
- Locations
- 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.